AVEO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVEO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AVEO Pharmaceuticals has the Growth Rank of 7.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, AVEO Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Growth Rank distribution charts can be found below:
* The bar in red indicates where AVEO Pharmaceuticals's Growth Rank falls into.
Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Jebediah Ledell | officer: Chief Operating Officer | C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Michael P Bailey | director, officer: President & CEO | IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014 |
Michael Ferraresso | officer: Chief Commercial Officer | AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Kevin Joseph Cullen | director | AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Epperly Corinne | director | AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Florence Anthony A. Jr. | 10 percent owner | 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
Forest Baskett | 10 percent owner | |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Scott D Sandell | 10 percent owner | |
Growth Equity Opportunities Iv, Llc | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Mohamad Makhzoumi | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Erick Lucera | officer: Chief Financial Officer | 138 THISTLE ROAD, NORTH ANDOVER MA 08145 |
Scarlett Spring | director | AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Peter J Barris | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By PRNewswire PRNewswire • 10-18-2022
By GuruFocusNews GuruFocusNews • 06-22-2022
By PurpleRose PurpleRose • 07-11-2022
By Stock market mentor Stock market mentor • 01-03-2023
By GuruFocusNews GuruFocusNews • 06-07-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By Ds*** Ds*** • 08-31-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By Business Wire Business Wire • 10-18-2022
By Stock market mentor Stock market mentor • 01-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.